Algert Global LLC Sells 28,373 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Algert Global LLC reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 57.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,341 shares of the medical equipment provider's stock after selling 28,373 shares during the period. Algert Global LLC's holdings in Lantheus were worth $1,909,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D raised its holdings in Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC raised its stake in shares of Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after buying an additional 129 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after acquiring an additional 132 shares during the period. Foundry Partners LLC increased its holdings in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 133 shares in the last quarter. Finally, UMB Bank n.a. raised its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Up 1.8 %

Lantheus stock traded up $1.42 during mid-day trading on Friday, reaching $81.86. 1,561,278 shares of the company's stock traded hands, compared to its average volume of 968,940. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89. The stock has a 50 day moving average of $99.57 and a two-hundred day moving average of $94.14. The company has a market cap of $5.61 billion, a price-to-earnings ratio of 13.62 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the prior year, the business posted $1.69 EPS. The company's revenue was up .8% on a year-over-year basis. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on LNTH shares. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday. Finally, StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.